TP53 and liver cancer: Research by Zhang et al. demonstrated that mutant activated β-catenin not only initiates liver tumorigenesis but also exacerbates liver cancer progression, particularly when combined with TP53 deletion or hepatitis B virus infection.302 Targeting β-catenin-activated AKT2-CAD-mediated pyrimidine synthesis has been suggested as a potential therapeutic approach for liver cancer.